Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 284)
eröffnet am 31.08.08 11:55:05 von
neuester Beitrag 10.08.23 11:06:43 von
neuester Beitrag 10.08.23 11:06:43 von
Beiträge: 4.229
ID: 1.143.896
ID: 1.143.896
Aufrufe heute: 0
Gesamt: 285.526
Gesamt: 285.526
Aktive User: 0
ISIN: US84763A1088 · WKN: 164623 · Symbol: NTR
0,8910
EUR
+4,97 %
+0,0450 EUR
Letzter Kurs 31.07.23 Tradegate
Neuigkeiten
20.07.23 · Business Wire (engl.)  |
30.06.23 · Business Wire (engl.) |
17.05.23 · Business Wire (engl.) |
09.05.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 1,2100 | +21,00 | |
| 27,50 | +19,57 | |
| 4,4900 | +19,10 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6400 | -18,81 | |
| 1,4500 | -20,55 | |
| 36,70 | -22,87 | |
| 2,3450 | -25,32 | |
| 15,600 | -31,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 37.264.345 von blb am 27.05.09 17:18:07Raj ist ein ausserordentlich ehrgeiziger CEO. Er sieht die Kursentwicklung der letzten Monate endlich als Chance seinen Traum von einem bedeutenden Biotechunternehmen zu beschleunigen. Finanzschwachen Biotechunternehmen interessante Wirkstoffe um Spottpreise abzukaufen, dieses Fenster bleibt nich ewig geöffnet und somit macht die Kapitalerhöhung Sinn. Auch wenn ich zugebe, dass es etwas inkonsequent wirkt in Relation zu den Aussagen des Managements in den letzten Monaten.
Ab er vermutlich ist es ähnlich abgelaufen wie bei der letzten KE von Dendreon. 1 Woche vorher wussten Sie noch gar nicht, dass sie eine machen wollen, dann kommen ein paar Institutionals (über die DB) und machen ein tolles Angebot und Boooom! eine 200 Mio $ KE zu attraktiven Preisen für das Unternehmen ist in wenigen Tagen über die Bühne.
Ab er vermutlich ist es ähnlich abgelaufen wie bei der letzten KE von Dendreon. 1 Woche vorher wussten Sie noch gar nicht, dass sie eine machen wollen, dann kommen ein paar Institutionals (über die DB) und machen ein tolles Angebot und Boooom! eine 200 Mio $ KE zu attraktiven Preisen für das Unternehmen ist in wenigen Tagen über die Bühne.
Antwort auf Beitrag Nr.: 37.263.579 von Magnetfeldfredy am 27.05.09 16:16:09Nee, war auf den Vorstand bezogen... Der hatte immer betont, wenn mögliche keine KE blablabla...
Antwort auf Beitrag Nr.: 37.262.620 von blb am 27.05.09 14:58:24Ich hab nicht von "keiner Verwässerung" geschrieben, Verwechslung?
Antwort auf Beitrag Nr.: 37.262.541 von Magnetfeldfredy am 27.05.09 14:49:50Soviel zum Thema "keine Verwässerung"... Naja wenigstens bekommen sie jetzt für die Aktien deutlich mehr als noch vor paar Monaten...
Antwort auf Beitrag Nr.: 37.259.047 von future_trader am 27.05.09 07:59:33Servus Future Trader,
vielleicht wird die kleine SPPI mal auch eine Dendreon, das Potentzial mit EOQuin wäre da, good news:
Spectrum Pharmaceuticals to Raise $20 Million from Institutional Investors at $5.11 Per Share, the Closing Bid Price on Tuesday, May 26, 2009
On Wednesday May 27, 2009, 8:30 am EDT
Buzz up! Print Related:Spectrum Pharmaceuticals, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI - News), a commercial-stage biotechnology company with a focus in oncology, today announced that it has received commitments from three institutional investors, led by Federated Kaufmann Fund, to purchase $20 million of securities in a registered direct offering. Spectrum expects to receive net proceeds of approximately $19 million after deducting placement agent fees and other offering expenses. Under the terms of a Securities Purchase Agreement, Spectrum will sell an aggregate of 3,913,894 shares of its common stock and warrants to purchase up to 1,956,947 additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase approximately one-half of a share of common stock, will be sold for a purchase price of $5.11, which is equal to the closing bid price of the Company’s common stock on Tuesday, May 26, 2009.
Related Quotes
Symbol Price Change
SPPI 5.13 0.00
{"s" : "sppi","k" : "c10,l10,p20,t10","o" : "","j" : ""} The warrants to purchase additional shares will be exercisable at an exercise price of $5.11 per share beginning six months after issuance and will expire 90 days from the date they are first exercisable. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes. The offering is expected to be consummated no later than May 29, 2009, subject to customary closing conditions.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM - News), acted as the exclusive placement agent for the transaction.
A shelf registration statement relating to the shares of common stock and warrants issued in the offering (and the shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the “SEC”) and has been declared effective. A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting Spectrum Pharmaceuticals, Inc., 157 Technology Drive, Irvine, California 92618. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The Company’s strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC. ® is a registered trademark of Spectrum, TURNING INSIGHTS INTO HOPE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
© 2009 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
vielleicht wird die kleine SPPI mal auch eine Dendreon, das Potentzial mit EOQuin wäre da, good news:
Spectrum Pharmaceuticals to Raise $20 Million from Institutional Investors at $5.11 Per Share, the Closing Bid Price on Tuesday, May 26, 2009
On Wednesday May 27, 2009, 8:30 am EDT
Buzz up! Print Related:Spectrum Pharmaceuticals, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI - News), a commercial-stage biotechnology company with a focus in oncology, today announced that it has received commitments from three institutional investors, led by Federated Kaufmann Fund, to purchase $20 million of securities in a registered direct offering. Spectrum expects to receive net proceeds of approximately $19 million after deducting placement agent fees and other offering expenses. Under the terms of a Securities Purchase Agreement, Spectrum will sell an aggregate of 3,913,894 shares of its common stock and warrants to purchase up to 1,956,947 additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase approximately one-half of a share of common stock, will be sold for a purchase price of $5.11, which is equal to the closing bid price of the Company’s common stock on Tuesday, May 26, 2009.
Related Quotes
Symbol Price Change
SPPI 5.13 0.00
{"s" : "sppi","k" : "c10,l10,p20,t10","o" : "","j" : ""} The warrants to purchase additional shares will be exercisable at an exercise price of $5.11 per share beginning six months after issuance and will expire 90 days from the date they are first exercisable. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes. The offering is expected to be consummated no later than May 29, 2009, subject to customary closing conditions.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM - News), acted as the exclusive placement agent for the transaction.
A shelf registration statement relating to the shares of common stock and warrants issued in the offering (and the shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the “SEC”) and has been declared effective. A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting Spectrum Pharmaceuticals, Inc., 157 Technology Drive, Irvine, California 92618. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The Company’s strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC. ® is a registered trademark of Spectrum, TURNING INSIGHTS INTO HOPE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
© 2009 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
Trading Spotlight
Antwort auf Beitrag Nr.: 37.259.047 von future_trader am 27.05.09 07:59:33Völlig Richtig!
spectrum zeigt zur Zeit deutlich seine Stärke. Des Weiteren zeigt die gestrige MMeldung, dass sich spectrum nicht über den Tisch ziehen lässt. Respekt. So gefällt mir das.
Das stetige hohe Volumen bei steigenden Kursen ist sehr posiv zu werten.
Im gestrigen After hour-Handel ging es nochmals bergauf.
Das stetige hohe Volumen bei steigenden Kursen ist sehr posiv zu werten.
Im gestrigen After hour-Handel ging es nochmals bergauf.
Antwort auf Beitrag Nr.: 37.253.068 von VaJo am 26.05.09 14:54:39Nee, knapp 775.000$! Die 3,5 Millionen sind die ursprüngliche Meilensteinzahlung, die sich Spectrum geweigert hat an CTIC zu zahlen.
VG blb
VG blb
Wieder 4,3 Mio Dollar mehr in der Tasche 
Spectrum Pharmaceuticals Wins Arbitration with Cell Therapeutics, Inc.
---------------------------
Tue May 26 07:00:04 2009 EDT
IRVINE, Calif., May 26, 2009 (BUSINESS WIRE) --
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a focus in oncology, announced today the
results of an arbitration dispute with Cell Therapeutics (CTI) with
regard to certain liabilities of CTI and joint venture expenses.
The arbitrator awarded Spectrum $4,276,454. Specifically, as set forth
in the arbitration award, $3.5 million was ordered to be immediately
released from the escrow account and distributed entirely to Spectrum.
Additionally, CTI was ordered to immediately pay an additional $776,454
to Spectrum by wire transfer.
Per the agreement, the arbitration award is final, binding, and
non-appealable by either party.
"We are very pleased with the outcome of the arbitration process, and
remain very excited about the commercial potential of ZEVALIN. We
continue to view the year ahead as a transformative period for Spectrum
Pharmaceuticals, and we are committed to executing on our strategy and
building sustainable shareholder value," said Raj Shrotriya, MD,
Chairman, Chief Executive Officer, and President of Spectrum
Pharmaceuticals.
---------------------------
Tue May 26 07:00:04 2009 EDT
IRVINE, Calif., May 26, 2009 (BUSINESS WIRE) --
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a focus in oncology, announced today the
results of an arbitration dispute with Cell Therapeutics (CTI) with
regard to certain liabilities of CTI and joint venture expenses.
The arbitrator awarded Spectrum $4,276,454. Specifically, as set forth
in the arbitration award, $3.5 million was ordered to be immediately
released from the escrow account and distributed entirely to Spectrum.
Additionally, CTI was ordered to immediately pay an additional $776,454
to Spectrum by wire transfer.
Per the agreement, the arbitration award is final, binding, and
non-appealable by either party.
"We are very pleased with the outcome of the arbitration process, and
remain very excited about the commercial potential of ZEVALIN. We
continue to view the year ahead as a transformative period for Spectrum
Pharmaceuticals, and we are committed to executing on our strategy and
building sustainable shareholder value," said Raj Shrotriya, MD,
Chairman, Chief Executive Officer, and President of Spectrum
Pharmaceuticals.
Durchsuchen
